Atossa Genetics Stock Today
| ATOS Stock | USD 0.75 0.03 4.14% |
PerformanceVery Weak
| Odds Of DistressLow
|
Atossa Genetics is selling for under 0.7498 as of the 19th of March 2025; that is 4.14 percent increase since the beginning of the trading day. The stock's lowest day price was 0.72. Atossa Genetics has less than a 10 % chance of experiencing some financial distress in the next two years of operation, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 19th of December 2024 and ending today, the 19th of March 2025. Click here to learn more.
Business Domain Health Care Equipment & Services | IPO Date 8th of November 2012 | Category Healthcare | Classification Health Care |
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington. The company has 125.8 M outstanding shares of which 8.99 M shares are presently shorted by private and institutional investors with about 13.82 trading days to cover. More on Atossa Genetics
Moving against Atossa Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Atossa Stock Highlights
| Business Concentration | Health Care Equipment & Supplies, Health Care Equipment & Services, Health Care, NASDAQ Composite, NASDAQ Health Care, NASDAQ Composite Total, Health Care, Health Care Equipment & Supplies, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsAtossa Genetics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Atossa Genetics' financial leverage. It provides some insight into what part of Atossa Genetics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Atossa Genetics (ATOS) is traded on NASDAQ Exchange in USA. It is located in 107 Spring Street, Seattle, WA, United States, 98104 and employs 12 people. Atossa Genetics is listed under Health Care Equipment & Supplies category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 91.86 M. Atossa Genetics conducts business under Health Care Equipment & Supplies sector and is part of Health Care industry. The entity has 125.8 M outstanding shares of which 8.99 M shares are presently shorted by private and institutional investors with about 13.82 trading days to cover.
Atossa Genetics currently holds about 125.54 M in cash with (20.94 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.99, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Atossa Genetics Probability Of Bankruptcy
Ownership AllocationAtossa Genetics holds a total of 125.8 Million outstanding shares. Almost 71.4 percent of Atossa Genetics outstanding shares are held by general public with 0.05 (percent) owned by insiders and only 28.55 % by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Atossa Ownership Details
Atossa Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Charles Schwab Investment Management Inc | 2024-12-31 | 301.6 K | |
| Bank Of New York Mellon Corp | 2024-12-31 | 289.7 K | |
| Susquehanna International Group, Llp | 2024-12-31 | 226.2 K | |
| Virtu Financial Llc | 2024-12-31 | 208.2 K | |
| Barclays Plc | 2024-12-31 | 192 K | |
| Qube Research & Technologies | 2024-12-31 | 189.6 K | |
| Connor Clark & Lunn Inv Mgmt Ltd | 2024-12-31 | 189.3 K | |
| Nuveen Asset Management, Llc | 2024-12-31 | 170.7 K | |
| Jane Street Group Llc | 2024-12-31 | 126.7 K | |
| Blackrock Inc | 2024-12-31 | 9.8 M | |
| Vanguard Group Inc | 2024-12-31 | 6.6 M |
Atossa Genetics Historical Income Statement
Atossa Stock Against Markets
Atossa Genetics Corporate Management
| RAC MSPH | VP of Regulatory Affairs and Quality | Profile | |
| Heather CPA | Senior Officer | Profile | |
| Michael Parks | Vice Relations | Profile | |
| Heather Rees | VP Accounting | Profile | |
| FCAP MD | CEO Chairman | Profile | |
| Delly PHR | Vice Resources | Profile | |
| Eric Zanten | Vice Relations | Profile |
Already Invested in Atossa Genetics?
The danger of trading Atossa Genetics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Atossa Genetics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Atossa Genetics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Atossa Genetics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Atossa Stock Analysis
When running Atossa Genetics' price analysis, check to measure Atossa Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atossa Genetics is operating at the current time. Most of Atossa Genetics' value examination focuses on studying past and present price action to predict the probability of Atossa Genetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Atossa Genetics' price. Additionally, you may evaluate how the addition of Atossa Genetics to your portfolios can decrease your overall portfolio volatility.